🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "huge turning point" in the effort against superbug strains of the infection, according to researchers.

A Global Public Health Issue

Cases of gonorrhoea are on the rise globally, with figures suggesting over 82 million new cases per year. Especially elevated rates are seen in the African continent and nations within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. Within England, cases have hit a record high, while figures across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The approval of fresh medications for gonorrhoea is an significant and necessary step in the context of increasing worldwide cases, escalating drug resistance and the highly restricted treatment choices at this time.”

Health officials are increasingly worried about the increase in treatment-resistant strains. The global health body has designated it as a "critical concern". Recent surveillance found that resistance to primary antibiotics like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Treatment Options Secure Authorization

Zoliflodacin, alternatively called Nuzolvence, was cleared by the US FDA in recent days for use against gonorrhoea. This STI can lead to significant complications, including infertility. Scientists anticipate that focused deployment of this new drug will help slow the emergence of superbugs.

Gepotidacin, developed by the drugmaker GlaxoSmithKline, was also approved in close succession. This medication, which is additionally indicated for urinary tract infections, was proven in research to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment was the result of a unique collaborative effort for drug creation. The charitable organization Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company Innoviva to bring it to fruition.

“This milestone represents a significant shift in the treatment of superbug gonorrhoea, which previously has been evolving faster than antibiotic development.”

Testing Data and Worldwide Availability

Based on data released by a prominent scientific publication, zoliflodacin cured more than 90% of uncomplicated infections. This places it at an equal footing with the existing first-line therapy, which combines two antibiotics. The research involved over 900 participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, GARDP has the rights to register and commercialise the drug in many developing nations.

Doctors on the front lines have shared hope. Having a easy-to-administer therapy of this kind is described as a "revolutionary step" for managing the epidemic. This is deemed crucial to reduce the burden of the infection for individuals and to stop the proliferation of untreatable gonorrhoea worldwide.